Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Raja Chaaba

University of Monastir, Tunisia

Title: Genotypic interactions of genes implicated in lipoprotein metabolism with type-2 diabetes in Tunisian population

Biography

Biography: Raja Chaaba

Abstract

The relationship between diabetes and lipids is complex. Lipid disturbance can be the result of diabetes but also can be the reason of disturbed glucose metabolism. Apolipoprotein A5 (apo A5), Apolipoprotein E (Apo E) and CETP (Cholesteryl Ester Transfer Protein) are involved in lipoprotein metabolism. To explore the role of genetic variants of apo A5, Apo E and CETP as predictors of diabetes risk and to examine their combined eff ects on type-2 diabetes mellitus (T2DM), 149 type-2 diabetic patients are compared to 101 controls. Th e genotypic frequencies for all three genes alone were associated with increased risk of developing diabetes. Logistic regression analysis of classic coronary risk factors and the genetic polymorphisms demonstrated that B2B2 and CC genotypes of CETP and apo A5 respectively were the most significant contributors to T2DM. However, those genotypes were not associated with higher CETP activity in diabetics. For the three genes, the risk of T2DM in individuals with one risk genotype was 2.5 (95% CI: 2.0-4.1, p=0.004) higher than those with zero risk genotype. Individuals who carried two risk genotypes had a 3.8 (95%CI 3.2-4.8, p=0.018) times higher risk of T2DM than those who did not carry any risk genotypes. Most interestingly, the risk of T2DM for individuals with three risk genotypes was 3.7 (95% CI: 3.5-4.2, p=0.015) higher than those with zero risk genotype. In conclusion, the results imply that genotyping of genes implicated in lipoprotein metabolism could become an important part of the clinical process of risk identifi cation for T2DM.